Description: Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
Home Page: www.syndax.com
SNDX Technical Analysis
35 Gatehouse Drive
Waltham,
MA
02451
United States
Phone:
781 419 1400
Officers
| Name | Title |
|---|---|
| Mr. Michael A. Metzger M.B.A. | CEO & Director |
| Dr. Briggs W. Morrison M.D. | Pres, Head of R&D and Director |
| Dr. Anjali Ganguli Ph.D. | Chief Bus. Officer |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Richard A. Heyman Ph.D. | Co-Founder |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board |
| Dr. Michael Downes Ph.D. | Co-Founder |
| Mr. Keith Alan Goldan CPA | Chief Financial Officer |
| Mr. Alexander Nolte | VP & Chief Accounting Officer |
| Sharon Klahre | VP of Investor Relations & Communications |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 122 |
| Price-to-Book MRQ: | 4.8719 |
| Price-to-Sales TTM: | 12.6667 |
| IPO Date: | 2016-03-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 59 |